Form 4: Processa Pharmaceuticals Director Receives Stock Grant
Insider Transaction (Form 4)
Sheila Gujrathi, a Director of Processa Pharmaceuticals, Inc., reported multiple transactions in common stock on July 28, 2026.
Summary
- Grant/award: acquired 70,812 Series A Preferred Stock on July 28, 2026; holds 70,812 after (Direct).
- Grant/award: acquired 12,311 Series A Preferred Stock on July 28, 2026; holds 12,311 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sheila Gujrathi — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-28 | Grant/award | Series A Preferred Stock | 70,811.877 | — | — | 70,811.877 |
| 2026-07-28 | Grant/award | Series A Preferred Stock | 12,311.279 | — | — | 12,311.279 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-28 | Grant/award (70,812 shares) |
| 2026-07-28 | Grant/award (12,311 shares) |
Keywords
insider transaction, Form 4, PCSA, Processa Pharmaceuticals, Inc., neutral, Sheila Gujrathi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.